老年肝细胞癌患者的免疫治疗
本文综述免疫检查点抑制剂(ICI)治疗肝细胞癌(HCC)的最新进展及其在老年患者中的疗效与安全性。III期试验中65岁以上患者比例分别为CheckMate 459的51%、KEYNOTE-240的58%和IMbrave150的50%,低于流行病学调查的70%-73%,提示试验人群可能不能准确代表真实世界老年HCC患者。
要点
- ICI通过阻断相关检查点激活T细胞,激发癌细胞天然抗肿瘤潜能。
- 衰老伴随免疫系统变化即免疫衰老,可能影响免疫治疗的抗肿瘤效果与安全性。
- III期试验中65岁以上HCC患者比例低于流行病学调查,影响疗效与安全性外推。
核心结论
- 本综述提供ICI治疗HCC的最新进展及其对老年患者疗效与安全性的相关信息,并讨论ICI对老年HCC患者的获益,提出开展进一步临床试验的相关建议以更完整回答该临床问题。
研究设计与样本
- 综述,总结ICI免疫治疗HCC的最新进展及老年患者疗效与安全性相关信息。
主要发现
- ICI可阻断相关检查点激活T细胞,激发癌细胞天然抗肿瘤潜能,以逆转肿瘤逃避免疫应答的现象。
- 衰老时免疫系统组分与功能发生一系列变化即免疫衰老,可能影响免疫治疗的抗肿瘤效果与安全性。
- III期试验中65岁以上HCC患者比例:CheckMate 459为51%,KEYNOTE-240为58%,IMbrave150为50%,低于流行病学调查的70%-73%。
临床怎么用
- 作者提出开展进一步临床试验的相关建议,以更完整回答老年HCC患者免疫治疗的临床问题。
局限性
- 临床试验招募的老年人群可能不能准确代表真实世界老年HCC患者,影响将试验所得疗效与安全性外推至真实世界老年人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular carcinoma (HCC) is one of the most common types of cancer globally and is currently the third leading cause of cancer-related deaths. Recently, immunotherapy using immune checkpoint inhibitors (ICIs) has been shown with encouraging anticancer activity and safety in clinical trials. To reverse the phenomenon of tumours evading immune response, ICIs can be used to stimulate the natural antitumour potential of cancer cells by blocking the relevant checkpoints to activate T cells. However, the components and functions of the immune system may undergo a series of changes with ageing, known as 'immunosenescence,' potentially affecting the antitumour effect and safety of immunotherapy. In the current phase III clinical trials of ICIs including nivolumab, pembrolizumab and atezolizumab, the proportion of patients with HCC older than 65 years in CheckMate 459, KEYNOTE-240 and IMbrave150 is 51%, 58% and 50%, respectively, which is less than 70%-73% of epidemiological investigation. Therefore, the elderly population recruited in clinical trials may not accurately represent the real-world elderly patients with HCC, which affects the extrapolation of the efficacy and safety profile obtained in clinical trials to the elderly population in the real world. This review provides the latest advances in ICIs immuno-treatment available for HCC and relevant information about their therapeutic effects and safety on elderly patients. We discuss the benefits of ICIs for older HCC patients, and relevant recommendations about conducting further clinical trials are proposed for more complete answers to this clinical issue.
引用
- Lyu N, Yi JZ, Zhao M, et al. Immunotherapy in older patients with hepatocellular carcinoma. Eur J Cancer. 2021. PMID: 34954439. doi:10.1016/j.ejca.2021.11.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。